NZ700274A - Anti-pdgf-c antibodies - Google Patents

Anti-pdgf-c antibodies

Info

Publication number
NZ700274A
NZ700274A NZ700274A NZ70027413A NZ700274A NZ 700274 A NZ700274 A NZ 700274A NZ 700274 A NZ700274 A NZ 700274A NZ 70027413 A NZ70027413 A NZ 70027413A NZ 700274 A NZ700274 A NZ 700274A
Authority
NZ
New Zealand
Prior art keywords
pdgf
antibodies
inhibiting
binding
pdgfrα
Prior art date
Application number
NZ700274A
Other languages
English (en)
Inventor
Richard Zwaal
Claudia Fromond
Sofie Notebaert
Hoa Thu Ngo
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Priority to NZ724395A priority Critical patent/NZ724395A/en
Publication of NZ700274A publication Critical patent/NZ700274A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ700274A 2012-04-24 2013-04-24 Anti-pdgf-c antibodies NZ700274A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ724395A NZ724395A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
EP12165314 2012-04-24
US201261727231P 2012-11-16 2012-11-16
EP12192943 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (1)

Publication Number Publication Date
NZ700274A true NZ700274A (en) 2016-10-28

Family

ID=49482233

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ724395A NZ724395A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies
NZ700274A NZ700274A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ724395A NZ724395A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Country Status (13)

Country Link
US (1) US9884910B2 (forum.php)
EP (1) EP2841454A1 (forum.php)
JP (1) JP2015515487A (forum.php)
KR (1) KR20150005631A (forum.php)
CN (1) CN104321343A (forum.php)
AU (1) AU2013254690B2 (forum.php)
BR (1) BR112014025560A2 (forum.php)
CA (1) CA2871528A1 (forum.php)
IN (1) IN2014DN09717A (forum.php)
MX (1) MX2014012843A (forum.php)
NZ (2) NZ724395A (forum.php)
RU (1) RU2014140116A (forum.php)
WO (1) WO2013160359A1 (forum.php)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014012843A (es) 2012-04-24 2017-01-23 Thrombogenics Nv Anticuerpos anti-pdgf-c.
CN108348605B (zh) * 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
WO2018005904A2 (en) * 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
KR102756155B1 (ko) * 2017-12-04 2025-01-20 라보라토리오스 에스에이엘브이에이티, 에스.에이. 도베실산을 포함하는 후안부 질환 치료를 위한 안과용 국소 조성물
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
US20250051435A1 (en) * 2023-08-11 2025-02-13 Invetx, Inc. Anti-il-5 antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
IL138488A0 (en) 1998-03-17 2001-10-31 Genentech Inc Polypeptides homologous to vegf and bmp1
WO2000018212A2 (en) 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
AU764039B2 (en) * 1998-12-07 2003-08-07 Zymogenetics Inc. Growth factor homolog ZVEGF3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2001028586A1 (en) 1999-10-21 2001-04-26 Zymogenetics, Inc. Method of treating fibrosis
CA2403829A1 (en) * 2000-03-28 2001-10-04 Ludwig Institute For Cancer Research Non-human transgenic animals expressing platelet-derived growth factor c (pdgf-c) and uses thereof
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
DK1660135T3 (da) 2003-07-25 2009-09-07 Zymogenetics Inc Fremgangsm de til at behandle hepatocellul re carcinomer
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
WO2007124308A2 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
MX2014012843A (es) 2012-04-24 2017-01-23 Thrombogenics Nv Anticuerpos anti-pdgf-c.

Also Published As

Publication number Publication date
NZ724395A (en) 2018-03-23
MX2014012843A (es) 2017-01-23
RU2014140116A (ru) 2016-06-10
EP2841454A1 (en) 2015-03-04
BR112014025560A2 (pt) 2017-07-04
WO2013160359A1 (en) 2013-10-31
US20150232546A1 (en) 2015-08-20
CA2871528A1 (en) 2013-10-31
US9884910B2 (en) 2018-02-06
IN2014DN09717A (forum.php) 2015-07-31
CN104321343A (zh) 2015-01-28
JP2015515487A (ja) 2015-05-28
AU2013254690B2 (en) 2017-12-07
AU2013254690A1 (en) 2014-11-06
KR20150005631A (ko) 2015-01-14

Similar Documents

Publication Publication Date Title
TN2015000396A1 (en) Antibody drug conjugates
NZ700274A (en) Anti-pdgf-c antibodies
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
PH12017500890A1 (en) Antibody drug conjugates
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EP3702372A3 (en) Anti-cd40 human antibodies
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
IN2014KN00848A (forum.php)
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
WO2014163714A3 (en) Antibody drug conjugates
PH12017500864A1 (en) Anti-notch1 antibodies
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
IN2014DN05885A (forum.php)
PH12015501243A1 (en) Compositions and methods for antibodies targeting epo
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
HK1196831A (en) Lsr antibodies, and uses thereof for treatment of cancer
HK1196856A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 APR 2018 BY DENNEMEYER + CO.

Effective date: 20170331

LAPS Patent lapsed